Vor Biopharma Inc. — Director's Dealing 2021

Feb 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vor Biopharma Inc. (VOR)
CIK: 0001817229
Period of Report: 2021-02-04

Reporting Person: Chakraborty Tirtha (Chief Scientific Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (3534)		Direct
Employee Stock Option (right to buy)	$1.36	2029-09-24	Common Stock (46246)		Direct
Employee Stock Option (right to buy)	$2.18	2030-03-09	Common Stock (24410)		Direct
Employee Stock Option (right to buy)	$1.90	2030-08-20	Common Stock (70656)		Direct
Employee Stock Option (right to buy)	$6.53	2030-11-17	Common Stock (121323)		Direct

Footnotes

F1: Each share of Series B Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 13.6-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: 1/4th of the shares underlying the option vested on September 23, 2020, with the remainder vesting in equal monthly installments over 3 years, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.

F3: 1/16th of the shares underlying the option vested on October 1, 2020, with the remainder vesting in equal monthly installments over 45 months,
provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.

F4: 1/48th of the shares underlying the option vest or vested in equal monthly installments commencing on December 16, 2020, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.